CVRx has launched the BENEFIT-HF clinical trial for its Barostim device, targeting a significant expansion in heart failure treatment. This pivotal study, enrolling 2,500 patients, could potentially triple the addressable market for Barostim and solidify its position in cardiac care, driving future revenue growth.
CVRx shares fell 29.8% to $8.10 in pre-market trading. The decline followed preliminary first quarter 2025 financial results. Other stocks also faced losses amid weak earnings reports. U.S. stock futures showed positive movement despite some company downturns. The Greed Index remains in an 'Extreme Fear' zone.